↓ Skip to main content

Dove Medical Press

Article Metrics

Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study

Overview of attention for article published in Neuropsychiatric Disease and Treatment, January 2018
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
19 Mendeley
Title
Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
Published in
Neuropsychiatric Disease and Treatment, January 2018
DOI 10.2147/ndt.s150550
Pubmed ID
Authors

Alessandro Introna, Eustachio D'Errico, Boris Modugno, Antonio Scarafino, Angela Fraddosio, Eugenio Distaso, Irene Tempesta, Antonella Mastronardi, Isabella Laura Simone

Abstract

Riluzole is the first drug approved to treat amyotrophic lateral sclerosis (ALS). Recently, an oral suspension (OS) of riluzole was made available. Thus, the aim of our study was to evaluate the adherence to 2 formulations of riluzole in patients with ALS. We enrolled 45 consecutive patients with ALS. At disease diagnosis, riluzole was prescribed in 2 different formulations depending on the severity of dysphagia (27/45 patients received tablets and 18/45 patients received OS). Side effects (SEs) and treatment adherence were investigated using a clinical questionnaire including the ©Morisky 8-item Medication Adherence Questionnaire. Gastroenteric complaints were the most frequent SEs (58% in the tablet group and 48% in the OS group), followed by those at the nervous system (29% and 40%, respectively). No serious SEs related to treatment were reported. The rate of adherence to riluzole was independent of the formulation of the drug and consistent with other medications assumed for comorbidities (p=0.004). In the tablet group, low adherence was caused by SEs in 55.6% and by dysphagia in 44.4% of patients. In the OS group, SEs caused low adherence in 75% of patients. Independently of the drug formulation, patients with high or medium adherence to riluzole had a higher progression rate (p=0.002 and p=0.009, respectively) and a shorter time to generalization (TTG; p=0.01), compared to those with low adherence. Gastroenteric symptoms were the most frequent SE related to tablet as well as OS. The rate of adherence was independent of the formulation of riluzole and the number of medications assumed for comorbidities, and it was consistent with the severity of the disease. The low adherence was caused by dysphagia and SEs in the tablet group, whereas it was caused prevalently by SEs in the OS group.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 21%
Student > Postgraduate 2 11%
Student > Master 2 11%
Student > Doctoral Student 2 11%
Student > Bachelor 1 5%
Other 2 11%
Unknown 6 32%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 26%
Medicine and Dentistry 2 11%
Nursing and Health Professions 1 5%
Psychology 1 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Other 1 5%
Unknown 8 42%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2018.
All research outputs
#12,950,487
of 14,687,926 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,964
of 2,442 outputs
Outputs of similar age
#335,544
of 398,968 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#63
of 76 outputs
Altmetric has tracked 14,687,926 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 398,968 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.